Board of Directors
Mr. Song QingExecutive Director,Chairman of the Board
Mr. Song Qing joined the Group in
August 2018 as an executive Director and the vice chairman, and has been
re-designated as the Chairman of the Board of the Group since April 2021. Mr.
Song has extensive experiences in corporate management, and has over 30 years
of experience and sophisticated background in the pharmaceutical industry. Mr.
Song is currently the chairman of China Resources Healthcare Group Limited
(which is principally engaged in investments in healthcare sector and operation
and management of medical institutes). Mr. Song was the director of China
Resources Pharmaceutical Group Limited (which is listed on the Main Board of
the Stock Exchange; stock code: 3320) from May 2016 to August 2018, and also
its president from June 2017 to August 2018. Mr. Song was the director of China
Resources Sanjiu Medical & Pharmaceutical Co Ltd (which is listed on
Shenzhen Stock Exchange; stock code: 000999) up to August 2018, and its
chairman of the board from June 2017 to August 2018. He also served as an
inspection pharmacist of quality inspection department, a pharmacist in charge
and the director of production department, the director of the enterprise
management department and an assistant to president of Shenzhen South
Pharmaceutical Factory. Mr. Song served as an assistant general manager, the
director of technology center, the director of medical & pharmaceutical
department of Sanjiu Enterprise.
Mr. Cheng LibingExecutive Director, Chief Executive Officer of the Group
Mr. Cheng Libing joined the Group in September 2010 and is primarily responsible for daily operations of the Group. He has been appointed as an executive Director and the vice Chairman in February 2016. He has also been re-designated as the Chief Executive Officer of the Company since August 2018. Mr. Cheng is currently the chairman of Beijing Jiangong Hospital Co., Ltd., the chairman of Run Neng Medical Management Co., Ltd., the chairman and general manager of China Resources Hospital Management Consulting Co., Ltd. and he is also the chairman and general manager of China Resources Hospital Investment (China) Co., Ltd., and he also director of certain other subsidiary of the Company. Prior to joining the Group, Mr. Cheng served as the deputy general manager of Beijing Huaren Intech Hospital Management Consulting Co., Ltd. (北京华仁英智医院管理咨询有限公司) from 2006 to 2008 and the deputy general manager of Beijing Huaren Intech Hospital Management Consulting Co., Ltd., Beijing Intech Eye Hospital Co., Ltd. (北京英智眼科医院有限公司) and Intech Medical Chain (英智医疗连锁机构) from 2008 to 2010. From 1999 to 2002, Mr. Cheng has served various positions at Beijing Kangchen Pharmaceutical Co., Ltd. (北京康辰医药发展有限公司), including assistant to the general manager. Mr. Cheng also served in various positions such as an attending doctor at Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (北京中医药大学附属东直门医院) from 1988 to 1998. Mr. Cheng received a bachelor’s degree in Clinical Traditional Chinese Medicine from Beijing University of Chinese Medicine (北京中医药大学) in July 1988. Mr. Cheng has a comprehensive and profound understanding of hospital management, social capital medical management, public hospitals and state-owned enterprise hospitals reform and the law of medical and health industry. He is a senior expert in the field of medical investment management, and is committed to making CR Medical bacome an international leading medical industry group, and promoting the vigorous development of China medical and health industry.
Ms. Ren YuanExecutive Director, Chief Financial Officer
Ms. Ren Yuan joined the Group in October 2017 as an executive Director and Chief Financial Officer. Prior to joining the Group, Ms. Ren worked as the deputy manager of the finance department of China Resources Microelectronics (Holdings) Limited (华润微电子（控股）有限公司) from June 2002 to December 2006. From February 2004 to February 2010, Ms. Ren served as the finance director of Wuxi CR Micro-Assembly Tech., Ltd. (无锡华润安盛科技有限公司). And Ms. Ren worked as the consultancy general director and deputy general director of the information management department of China Resources (Holdings) Co., Ltd. (华润（集团）有限公司) since March 2010. Ms. Ren obtained her master’s degree in accounting from the Chinese University of Hong Kong (香港中文大学) in December 2007. Ms. Ren obtained the qualifications of China Certified Public Accountant (中国注册会计师) and China Certified Public Valuer (中国注册资产评估师) in December 1998 and September 1999 respectively.
Ms. Fu YanjunExecutive Director, Deputy General Manager
Ms. Fu Yanjun joined the Group in December 2014 and has been appointed as the deputy general manager of the Company since December 2016. In October 2017, Ms. Fu has been appointed as an executive Director. Ms. Fu She is currently also the chairman of the youth committee of the Group. Ms. Fu has been appointed as a supervisor of Beijing Jingkelong Company Limited (stock code: 814) since May 2017. Ms. Fu also worked for Ernst & Young Hua Ming from September 2002 to October 2010 and Deloitte Touche Tohmatsu CPA Ltd. From October 2010 to December 2014. Ms. Fu obtained a bachelor’s degree in accounting from Renmin University of China (中国人民大学) in July 2002 and obtained the qualification of China Certified Public Accountant (中国注册会计师) in May 2008.
Mr. Wang YanNon-executive Director
Mr. Wang Yan has been appointed as a nonexecutive Director from November 2016. He joined China Resources National Corporation in August 1994. From February 2016, Mr. Wang has been appointed as the general manager of internal audit department of CR Holdings. Since August 2014, Mr. Wang has been appointed as the non-executive director of China Resources Cement Holdings Limited (stock code: 1313), China Resources Gas Group Limited (stock code: 1193), China Resources Land Limited (stock code: 1109) and China Resources Power Holdings Company Limited (stock code: 836). From August 2014 to April 2016, Mr. Wang was a non-executive director of China Resources Beer (Holdings) Company Limited (stock code: 291). Mr. Wang obtained a bachelor’s degree in economics from the Finance and Accounting Department, Capital University of Economics and Business and obtained a master’s degree in Business Administration from the University of South Australia. Mr. Wang is a qualified PRC Certified Accountant.
Mr. Wu Ting YukIndependent Non-executive Director
Mr. Wu Ting Yuk, Anthony joined the Group in August 2018 as an independent non-executive Director and the chairman He has tendered his resignation as the Chairman of the Board, and remains as an independent non-executive Director since April 2021. Mr. Wu is a leader in the healthcare industry and has extensive management experience in medical system. Mr. Wu joined the board of the Hong Kong Hospital Authority in 1999 and was formerly its chairman from 2004 to 2013. He has so far been the longest-serving chairman of the Hospital Authority. Mr. Wu is currently the principal advisor to the State Administration of Traditional Chinese Medicine of the People’s Republic of China, a member of the Chinese Medicine Reform and Development Advisory Committee. He was a member of the State Council’s Medical Reform Leadership Advisory Committee and an advisor to the Public Policy Advisory Committee of the National Health and Family Planning Commission. Other important public positions that Mr. Wu has served include member of the 12th and 13th Standing Committee of the Chinese People’s Political Consultative Conference National Committee, and a member of the Chief Executive’s Council of Advisers on Innovation and Strategic Development and the Task Force on Land Supply of the Hong Kong SAR, and has been awarded JP and GBS by the government of Hong Kong SAR. Mr. Wu also served as the chairman of the Chamber Council of the Hong Kong General Chamber of Commerce from 2010 to 2012, and is currently a member of its consultation committee. Mr. Wu was a partner of Ernst & Young (“EY”) from 1985 to 2015, and served as chairman of the EY’s Far East Region from 2000 to 2005. He is currently the chief advisor to MUFG Bank, Ltd., the chairman of The China Oxford Scholarship Fund, an honorary professor of the Faculty of Medicine of the Chinese University of Hong Kong and the Peking Union Medical College Hospital, and an honorary fellow of the Hong Kong College of Community Medicine. Mr. Wu also has directorships in certain listed companies of the Main Board of the Stock Exchange: he is an independent non-executive director of Power Assets Holdings Limited (stock code: 006), Guangdong Investment Limited (stock code: 270), China Taiping Insurance Holdings Company Limited (stock code: 966), Cstone Pharmaceuticals (stock code: 2616), Venus Mecttech (Hangzhou) Inc. (stock code: 2500) and Ocumension Therapeutics (stock code: 1477) . He was an executive director of Sincere Watch (Hong Kong) Limited (stock code: 444). He was also an independent nonexecutive director of Agricultural Bank of China Limited (stock code: 1288) from 2009 to 2015. He was also a director of the Fidelity Funds from 2011 to 2014. Mr. Wu is a fellow of the Hong Kong Institute of Certified Public Accountants and the Institute of Chartered Accountants in England and Wales, and the honorary chairman of the Institute of Certified Management Accountants (Australia) Hong Kong Branch.
Mr. Kwong Kwok KongIndependent Non-Executive Director
Mr. Kwong Kwok Kong has been appointed as an independent non-executive Director from September 2013. Mr. Kwong is currently as a Director of Yuen Long District Healthy City Association Company Limited, a non-profit organization supporting the government to promote public healthcare messages to people in the district. Mr. Kwong was the chief executive officer of Pok Oi Hospital, a well-known non-profit hospital in Yuen Long District, Hong Kong. He joined Pok Oi Hospital as an internal audit manager in 2003. Prior to joining Pok Oi Hospital, Mr. Kwong served as the principal auditor of the Audit Commission of the Government of the Hong Kong Special Administrative Region. Mr. Kwong served in the Audit Commission of the Government of Hong Kong since 1980. Mr. Kwong has been a member of the Hong Kong Institute of Certified Public Accountants since 1982.
Ms. Chiu Kam Hing KathyIndependent Non-Executive Director
Ms. Chiu Kam Hing Kathy has been appointed as an independent non-executive Director from March 2018. Ms. Chiu is the chairman of Prime Investments Group Limited and is currently an independent non-executive director of Sau San Tong Holdings Limited (stock code: 8200) and CPM Group Limited (stock code: 1932), whose shares are all listed on the Stock Exchange. She was also an independent non-executive director of National Agricultural Holdings Limited (stock code: 1236) from 1999 to 2019. Ms. Chiu has years of banking experience in Canada and the Asia Pacific Region. Ms. Chiu was a senior vice president at the Republic National Bank of New York and was responsible for the management and investment of third party client’s funds. Ms. Chiu has been an associate and a fellow of the Institute of Canadian Bankers since July 1975 and August 1976 respectively. Ms. Chiu was appointed as a Justice of the Peace by the Hong Kong government in July 1992 and as a Cavaliere by the Italian Government in December 1998. Ms. Chiu is licenced to carry out asset management business under Type 9 regulated activities under the SFO.
Mr. Lee Kar Chung FelixIndependent Non-Executive Director
Mr. Lee Kar Chung Felix joined the Group in August 2015 as an independent non-executive Director. He is currently a senior vice president of Chow Tai Fook Enterprises Limited (“CTFE”) with responsibilities in making investments in the healthcare sector in Asia and globally and a director of Healthcare Ventures Holdings Limited, a wholly owned subsidiary of CTFE. Mr. Lee is also an executive director of UMP Healthcare Holdings Limited (stock code: 722; CTFE is a substantial shareholder of this company). He has over 15 years of experience in law and finance. He was an associate with the law firm Freshfields Bruckhaus Deringer before he left in February 2008 to join UBS AG, Hong Kong branch as an analyst in the investment banking department until January 2009. He then joined the investment banking department of Deutsche Bank AG, Hong Kong branch and last held the position of director in the Corporate Advisory Group, where he worked from January 2009 to August 2014. Mr. Lee obtained a Bachelor of Laws from the London School of Economics and Political Sciences and a Postgraduate Certificate in Laws from the University of Hong Kong in July 2003 and June 2004, respectively. He is a solicitor of the High Court of Hong Kong since September 2007 and a solicitor (non-practising) in the Senior Courts of England and Wales since February 2013. Mr. Lee is also a Vice Chairman of the China Committee, the Hong Kong General Chamber of Commerce.